title: Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.
abstract: OBJECTIVE
  Women with breast cancer that initially involves local lymph nodes have a higher risk for local recurrence or developing metastases. Recent data suggest that germline polymorphism is a significant, previously unrecognized factor in breast cancer progression and metastasis. We assessed the influence of 16 selected common germline polymorphisms in disease-free survival and overall survival among 216 women diagnosed with lymph node-positive breast cancer.
  
  
  RESULTS
  The rare allele of FAS 1377G>A was significantly associated with prolonged disease-free survival (P = 0.012, risk ratio of recurrence (RR) = 0.557, 95% confidence interval (CI) = 0.353-0.878) in univariate analysis. After adjusting for known breast cancer prognostic factors the association remained significant (P = 0.050, RR = 0.500, CI = 0.309-0.809). In overall survival analysis we found a significant association of the FAS 1377G>A (P = 0.040, RR = 0.451, CI = 0.496-1.188) and IL10 592C>A polymorphisms (P = 0.020, RR = 1.707, CI = 1.087-2.680) in the univariate Cox regression. The effect remained statistically significant in the multivariate analysis for the IL10 592C>A polymorphism (P = 0.013, RR 1.841, CI 1.140-2.973). No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival.
  
  
  CONCLUSIONS
  Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.
authors.affiliation: Department of Internal Medicine, Division of Oncology, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
authors.forename: Gudrun
authors.initials: G
authors.lastname: Knechtel
authors.forename: Günter
authors.initials: G
authors.lastname: Hofmann
authors.forename: Armin
authors.initials: A
authors.lastname: Gerger
authors.forename: Wilfried
authors.initials: W
authors.lastname: Renner
authors.forename: Tanja
authors.initials: T
authors.lastname: Langsenlehner
authors.forename: Joanna
authors.initials: J
authors.lastname: Szkandera
authors.forename: Gerald
authors.initials: G
authors.lastname: Wolf
authors.forename: Hellmut
authors.initials: H
authors.lastname: Samonigg
authors.forename: Peter
authors.initials: P
authors.lastname: Krippl
authors.forename: Uwe
authors.initials: U
authors.lastname: Langsenlehner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D018095:Germ-Line Mutation; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D019014:fas Receptor / Q000235:genetics*
chemical_list: D019014:fas Receptor; D016753:Interleukin-10